# RETEVMO
> **NDA218160** · New Drug Application · Sponsor: ELI LILLY AND CO · Approved 2024-04-10
## Drug
- **FDA Application Number:** NDA218160
- **Application type:** New Drug Application
- **Brand name:** RETEVMO
- **Generic name:** SELPERCATINIB
- **Active ingredients:** SELPERCATINIB
- **Dosage form:** CAPSULE
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** ELI LILLY AND CO
- **Manufacturer:** Eli Lilly and Company
- **First approval:** 2024-04-10
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218160)
---
*AI Analytics · CC0 1.0*